Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
119 hedge funds and large institutions have $1.15B invested in Ra Pharmaceuticals, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 59 increasing their positions, 27 reducing their positions, and 16 closing their positions.
119% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 27
6% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 16
1% more funds holding
Funds holding: 118 → 119 (+1)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
11% less capital invested
Capital invested by funds: $1.29B → $1.15B (-$140M)
28% less call options, than puts
Call options by funds: $359K | Put options by funds: $499K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$63.6M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$21.8M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
+$19.1M |
| 4 |
BlackRock
New York
|
+$18.7M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$25.6M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$9.02M |
| 3 |
D.E. Shaw & Co
New York
|
-$7.68M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.36M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.78M |
RARX Hedge Fund Activity: Q3 2019 in Review
119 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q3 2019, worth a combined $1.15B — down 11% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RARX positions and 16 closed out — a net gain of 1 holder — while 59 added to existing stakes and 27 trimmed.
The largest buyer was Invesco, adding an estimated $63.6M. The largest seller was Wellington Management Group, cutting an estimated $25.6M.
- 119 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q3 2019, up from 118 in Q2 2019.
- Funds reported $1.15B of Ra Pharmaceuticals, Inc. Common Stock stock for Q3 2019, down 11% quarter-over-quarter.
- 17 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q3 2019 and 16 closed out, a net change of +1 holder.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q3 2019 was Invesco, an estimated $63.6M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q3 2019 was Wellington Management Group, an estimated $25.6M sold.
Based on aggregated 13F filings for Q3 2019.